May 20, 2008 – Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy with Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva® (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.Perforomist Inhalation Solution was approved in 2008 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA-approved nebulized formoterol fumarate... Dey's Press Release -
